Cerus (CERS) stock
CERS's Quality Score fell 1 point on Tue, Nov 3, to 6. Its daily price swings got bigger (3 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on CERS
| Since its Nov 2021 high | Down 70% |
| Latest filing | 8-K, Nov 2 |
CERS in the news
ReportMon Nov 2: the results are out. Kept its outlook for the year. Past reports ›
Mon Nov 2Cerus reported diluted EPS of $-0.00
CERS catalysts
After its last 4 reports it closed -2.1% on average, higher 1 of 4 times.
Why CERS scores 6
Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
- +5Chart checks 5 of 14 firing right now, one point each
- +3News positive trial data, earnings release
- Long-term trend subtracts
- Cash flow subtracts
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
CERS has 5 of 14 chart checks firing
CERS RSI on Nov 3: 47.7, below its 50-day and 200-day averages
- RSI 1447.7
- MACD (12, 26, 9)Above signal
- 50-day average$2.45
- 200-day average$2.45
- 50/200 crossGolden cross
- ADX 1419.6
- Support$2.33
- Resistance$2.68
- 52-week high$3.47
- 52-week low$1.38
- Chart patternFalling channel
- Bollinger Bands (20, 2)Inside
- Volume1.8x
The deep dive on CERS
- What it does and how it makes moneySEC filing · Mar 2, 2026SEC filing · Mar 2, 2026
- Where it stands
- What changed in its filingsSEC filing · Mar 2, 2026
- Who holds and trades it
How CERS ranks in Medical Devices
CERS is #33 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 33 |
When does CERS report earnings, and what happens after?
Expected to report Mon Mar 1, after the close (in 117 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What CERS reported on Nov 2, 2026
The quarter
The figures are not read from the release yet.
“Third quarter growth was driven by higher U.S. IFC sales, strength of the U.S. platelet franchise, and INT200 illuminator sales in EMEA.”
Where the sales came from
CERS's results filing gives no sales by line in a table we read.
The outlook
| Measure | Figure |
|---|---|
| Product revenue | $229M to $231M |
In the company's words
“The year-over-year decrease in gross margin was largely driven by a weaker U.S. dollar relative to the euro and higher product costs driven by inflationary pressures offset partially by pricing and favorable product mix shift.”
From its results filing (SEC filing · Nov 2)
The numbers
- $492M
- today
- -$1.8M
- last 12 months
Sales grew 15% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 3.1% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Nov 2, 2026 | -10.2% | -0.8% | open |
| Jul 30, 2026 | -15.9% | -25.6% | -19.7% |
| Apr 30, 2026 | +32.5% | +34.0% | +28.6% |
CERS sales and profit by year
Sales grew in six of the last seven years, to $234M in 2025. It lost money in each of the eight years.
Insiders trading CERS
CERS insider trades
One insider sold $53K across 1 filing in the last 6 months. No open-market buys on record. The newest:
CERS's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold CERS?
In ETFs: CERS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About Cerus
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
What Cerus says it competes with
“Our products face a wide variety of competition from entities competing directly with alternative pathogen reduction technologies for platelets and/or plasma, as well as from entities developing and selling blood screening products to detect and prevent contaminated products from being transfused, and from process and procedural decisions involving blood banking operations including but not limited to shortened shelf-life of blood components.”
CERS's score card
Pro members see every line of every stock's score.
- What would turn CERS's score around: 7 things
- 2 more filings explained, a plain line each
- Real-time prices, no delay
Straight Answers
Is CERS a good stock to buy? What its Quality Score says
CERS scores 6 today, which Breakaway calls Average. It is #33 of 85 in Medical Devices by Quality Score, with 5 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is CERS's Quality Score?
CERS scores 6 today, which Breakaway calls Average (6 to 10). That is #33 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CERS's 6.
Are insiders buying CERS?
One insider sold $53K across 1 filing in the last 6 months. No open-market buys on record. The newest is Eric Bjerkholt, Director, who sold $53K on Jun 9.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.